The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

Zika virus (ZIKV) has been known for decades to circulate in Africa and Asia. However, major complications of a ZIKV infection have recently become apparent for reasons that are still not fully elucidated. One of the hypotheses for the seemingly increased pathogenicity of ZIKV is that cross-reactive...

Full description

Saved in:

Bibliographic Details
Published in:	PLoS pathogens 2019-04, Vol.15 (4), p.e1007640-e1007640
Main Authors:	Langerak, Thomas, Mumtaz, Noreen, Tolk, Vera I, van Gorp, Eric C M, Martina, Byron E, Rockx, Barry, Koopmans, Marion P G
Format:	Article
Language:	eng
Subjects:	Achievement tests Analysis Antibodies Arthropods Biology and life sciences Child health Complications Congenital anomalies Congenital defects Cytomegalovirus Dengue fever Dengue hemorrhagic fever Dengue virus Dengue viruses Fetuses Genetic disorders Health aspects Health risks Hemorrhagic fevers Immune system Immunoglobulins Infection Infections Medical research Medicine and Health Sciences Medicine, Experimental Microcephaly Pathogenesis Pathogenicity Pathogens Placenta Pregnancy Review Risk factors Vector-borne diseases Viral antibodies Viral diseases Viruses West Nile virus Zika virus Zika virus infection
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Zika virus (ZIKV) has been known for decades to circulate in Africa and Asia. However, major complications of a ZIKV infection have recently become apparent for reasons that are still not fully elucidated. One of the hypotheses for the seemingly increased pathogenicity of ZIKV is that cross-reactive dengue antibodies can enhance a ZIKV infection through the principle of antibody-dependent enhancement (ADE). Recently, ADE in ZIKV infection has been studied, but conclusive evidence for the clinical importance of this principle in a ZIKV infection is lacking. Conversely, the widespread circulation of ZIKV in dengue virus (DENV)-endemic regions raises new questions about the potential contribution of ZIKV antibodies to DENV ADE. In this review, we summarize the results of the evidence to date and elaborate on other possible detrimental effects of cross-reactive flavivirus antibodies, both for ZIKV infection and the risk of ZIKV-related congenital anomalies, DENV infection, and dengue hemorrhagic fever.
ISSN:	1553-7374 1553-7366 1553-7374